Nvidia’s Q3 FY27: The Reassurance Before the Storm
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
@evfcfaddict @alluvialcapital $BWEL will work eventually
Tom likes the stock. $MKL adding >10% buyback auth, now ~15% buyback auth outstanding.
Target Posts Strongest Sales Growth in Years as Focus on New Products, Value Pays Off $TGT
TJX Raises Full-Year Outlook, Expects Sales Trends to Accelerate Through Holiday Season $TJX
Cal-Maine Foods to Cull 1.76 Million Birds After Florida Facility Tests Positive for Bird Flu $CALM
Nvidia faced China workaround enforcement concerns as technology fell 6%; energy rose 4.5%, while the company raised eFY28 revenue growth…
MiniMed's 15.8% Q1 organic growth and 20% U.S. pump-volume increase support a product-cycle recovery as split-off selling fades.
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and guided $130 billion, while Jensen Huang’s resignation left Colette Kress as…
Pfizer’s Q3 revenue reached $16.58 billion, launched and acquired products grew 32%, and FY26 guidance rose to $62 billion to $64 billion.
NVIDIA’s fiscal third-quarter 2027 results are its first earnings report since Jensen Huang’s resignation as CEO.
UFP Industries trades near its 2022 price despite EPS falling 62%; a $95–$105 valuation assumes $6.30 normal-year EPS, with freight and…
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and raised its fiscal 2028 growth outlook to 75% as interim CEO Colette Kress…
Century Aluminum (CENX) could benefit from U.S. tariffs, Midwest aluminum premiums and constrained global supply, with the stock trading…
Figma grew Q3 revenue 43% to $391.4 million, raised FY2026 guidance to nearly $1.5 billion and guided Q4 above consensus despite the stock…
Nvidia raised its fiscal 2028 growth outlook, but shares reversed as investors focused on uncertainty beyond January 2028.
KRYS · short Krystal Biotech is a profitable commercial-stage biotech with an $8.7 billion enterprise value and one FDA-approved topical gene therapy,…
Large active managers cluster in Visa, Mastercard, S&P Global, FICO, Alphabet, Meta and Berkshire, challenging alpha in widely owned…
ZhongAn Online trades at 0.57 times book after five profitable underwriting years, with a 95.8% combined ratio and ZA Bank’s first…
Steve Eisman argues the AI boom hinges on Anthropic and OpenAI’s importance to hyperscalers, while weighing software, CoreWeave and Cisco…
DNOW’s MRC Global merger targets $75 million of synergies, with a 2029 bull case of $30 to $32 per share driven by cash flow and rerating.
Nvidia GPU rental prices are rising across generations, supporting a $500 billion push to finance AI compute as a durable, rentable asset…
CoreWeave and Nebius cite AI compute shortages and higher-priced GPU renewals, but older-chip utilization and depreciation vary across…
Cellebrite cut 2026 ARR guidance by $15 million, replaced its CEO and saw shares fall 30% as elongated sales cycles raise execution…
NRP has retired debt and preferred stock, leaving 13 million acres of mineral rights to fund higher cash distributions, buybacks and soda…
Nintendo’s Switch 2 sold 23 million units in its first year, but software delays, memory-chip costs and yen weakness drove NTDOY from $25…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.